Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Incyte
< Previous
1
2
3
4
Next >
Incyte to Present at Upcoming Investor Conferences
December 15, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte’s Novel Mutant CALR Antibody Unveiled at ASH 2022 Plenary Scientific Session
December 11, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Data from Two LIMBER Studies Evaluating Combination Treatments in Patients with Myelofibrosis (MF) Presented at ASH 2022
December 10, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte and CMS Announce Collaboration and License Agreement for Ruxolitinib Cream in Greater China and Southeast Asia
December 02, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conferences
November 17, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
November 07, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
More than 50 Abstracts from Incyte’s Robust Oncology Portfolio to be Featured at the 64th ASH Annual Meeting
November 03, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
November 01, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Pivotal Phase 3 Data Showing Significant Improvements in Facial and Total Body Repigmentation with Ruxolitinib Cream (Opzelura™) in Vitiligo Published in New England Journal of Medicine
October 19, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Third Quarter Financial Results
October 11, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Names New Member to Its Board of Directors
October 04, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody
October 03, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
August 26, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Data from Incyte’s Dermatology Portfolio Accepted for Presentation at the 2022 European Academy of Dermatology and Venereology (EADV) Congress
August 24, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
August 23, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 02, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream for the Treatment of Vitiligo
July 18, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report Second Quarter Financial Results
July 12, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
May 26, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
May 24, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
May 05, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
May 04, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
May 03, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
April 28, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
April 22, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Report First Quarter Financial Results
April 12, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura™) in Patients With Vitiligo
March 26, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
March 25, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting
March 18, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
Incyte to Present at Upcoming Investor Conference
February 15, 2022
From
Incyte
Via
Business Wire
Tickers
INCY
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.